KA
Therapeutic Areas
Rigel Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TAVALISSE (fostamatinib) | Chronic Immune Thrombocytopenia (ITP) | Marketed |
| REZLIDHIA (olutasidenib) | Relapsed/Refractory AML with IDH1 mutation | Marketed |
| GAVRETO (pralsetinib) | RET+ Non-Small Cell Lung Cancer | Marketed |
| IRAK1/4 Inhibitor | Lower-Risk Myelodysplastic Syndrome (LR-MDS) | Phase 1b |
| RIPK1 Inhibitor | Immunological Diseases | Preclinical/Discovery |
Leadership Team at Rigel Pharmaceuticals
RR
Raul R. Rodriguez
President and Chief Executive Officer
DS
Dean Schorno
Executive Vice President and Chief Financial Officer
DA
David A. Santos
Executive Vice President and Chief Commercial Officer
LR
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
RJ
Raymond J. Furey
Executive Vice President, General Counsel and Corporate Secretary
JL
Joseph Lasaga
Executive Vice President and Chief Business Officer
JP
Julie Patel
Senior Vice President, Human Resources
MW
Mark W. Frohlich
Board Director